I gave a buy rating to Cellebrite (NASDAQ: CLBT ) in August as I believed the upside is no longer attractive given that valuation has risen to 31x forward EBITDA. Looking at how the share price hasI'm a passionate investor with a strong foundation in fundamental analysis and a keen eye for identifying undervalued companies with long-term growth potential. My investment approach is a blend of value investing principles and a focus on long-term growth. I believe in buying quality companies at a discount to th ...